Table 2.
Characteristics of measurable lesions
| Tumor entity | MD (n = 177)1 | Patients with ≥ 10 RECIST available lesions 1 | Patients with 1–9 RECIST available lesions 1 | Number of lesions  2
|
Lesion size  (mm) 2
|
Number of affected sites  †2
|
|---|---|---|---|---|---|---|
| Breast cancer | 35 (64%) | 12 (34%) | 23 (66%) | 3 (2.4) | 21 (9.5) | 2 (0.5) |
| Colorectal | 29 (91%) | 15 (52%) | 14 (48%) | 4 (2.6) | 28 (12.9) | 2 (0.7) |
| Hepatopancreaticobiliary | 18 (67%) | 9 (50%) | 9 (50%) | 2 (1.3) | 28 (15.5) | 2 (1.1) |
| Ovarian carcinoma | 12 (55%) | 3 (25%) | 9 (75%) | 4 (2.3) | 34 (17.6) | 2 (0.6) |
| Urologic cancers | 12 (67%) | 3 (25%) | 9 (75%) | 3 (1.5) | 27 (12) | 2 (0.9) |
| Sarcoma | 12 (71%) | 5 (42%) | 7 (58%) | 3 (2.2) | 47 (19.5) | 3 (1.3) |
| Thyroid cancer | 11 (65%) | 3 (27%) | 8 (73%) | 4 (2.1) | 22 (5.7) | 3 (1.1) |
| Other | 10 (67%) | 1 (10%) | 9 (90%) | 3 (2.0) | 31 (20.7) | 2 (0.9) |
| Neuroendocrine | 10 (77%) | 7 (70%) | 3 (30%) | 1 (0.5) | 33 (2.9) | 3 (0.8) |
| Endometrial and cervical cancer | 9 (69%) | 1 (11%) | 8 (89%) | 4 (2.7) | 29 (17.2) | 2 (0.8) |
| Cancer of unknown primary | 7 (64%) | 3 (43%) | 4 (57%) | 6 (2.7) | 24 (5.0) | 2 (1.3) |
| Gastric cancer | 3 (38%) | / | 3 (100%) | 3 (0.8) | 17 (2.2) | 1 (0.5) |
| Head and neck | 3 (50%) | / | 3 (100%) | 2 (0.5) | 23 (6.6) | 2 (0.9) |
| Malignant melanoma | 4 (80%) | 1 (25%) | 3 (75%) | 4 (0.9) | 39 (22.5) | 3 (0.5) |
| Pulmonary | 2 (67%) | 1 (50%) | 1 (50%) | 7 (n.a) | 23 (n.a) | 2 (n.a) |
MD, measurable disease; NMD, non-measurable disease; SD, standard deviation
1 n (%); 2 n (SD); Mean number of lesions and mean lesion size were calculated in patients with 1–9 RECIST available lesion; † The number of affected sites was documented for MD and NMD and was listed as followed; liver, lung, lymphatic system, bone, local recurrence (non-liver or pulmonary), or other (e.g. peritoneal)